AI Meets Biotech: The Future Of Protein Therapeutics With Mike Nally And Jason Silvers

In this episode of FYI – For Your Innovation, Brett Winton and ARK analyst Nemo Despot sit down with Generate Biomedicines CEO Mike Nally and CFO Jason Silvers to explore how generative AI is transforming the discovery and development of protein-based therapeutics. Founded in 2018 by Flagship Pioneering, Generate Biomedicines is building a “self-driving lab” that combines machine learning, cryo-electron microscopy (cryo-EM), and high-throughput wet lab automation to dramatically accelerate drug development. The conversation dives into how Generate is reimagining protein therapeutics — going beyond trial-and-error methods to a data-first, design-driven model for creating novel medicines. The team discusses the company’s proprietary approach to integrating structural biology with functional data, the economic implications of reducing time-to-market from 13 years to under 9, and how their platform could unlock treatments for diseases that have been historically undruggable. They also touch on strategic partnerships, scalability, and how AI is shifting the biotech business model from artisanal science to an industrialized, data-driven enterprise.

“We can actually drug what is considered today the undruggable and solve some of the greatest unmet needs facing humanity.” — Jason Silvers

Key Points From This Episode:

• 00:01:30 Why Generate Biomedicines is rethinking protein drug discovery from first principles
• 00:04:40 How their structure-first approach differs from peers like AbSci and Recursion
• 00:07:04 Using cryo-EM to build proprietary protein interaction datasets
• 00:10:57 Traditional drug discovery is random, expensive, and inefficient — here’s how Generate is changing that
• 00:16:58 From concept to clinic in 18–24 months: Accelerating timelines through AI
• 00:20:47 Going beyond efficiency: Unlocking access to undruggable biology
• 00:24:48 Turning cryo-EM into a high-throughput data engine for model training
• 00:31:20 The long-term vision: Patient-specific protein therapeutics
• 00:40:00 Why scalability gives Generate an edge over traditional biotech
• 00:47:52 The future of biotech as a research & development (R&D) sharing economy
• 00:54:19 Adapting fast: Keeping pace with generative AI advances across the stack
• 01:00:16 The KPI (key performance indicator) for platform success: Rate of improvement